Keros Therapeutics Files 8-K
Ticker: KROS · Form: 8-K · Filed: Jan 21, 2025 · CIK: 1664710
| Field | Detail |
|---|---|
| Company | Keros Therapeutics, Inc. (KROS) |
| Form Type | 8-K |
| Filed Date | Jan 21, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001, $200.0 m |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, financial-statements, exhibits
TL;DR
Keros filed an 8-K with financial docs, nothing major announced yet.
AI Summary
Keros Therapeutics, Inc. filed an 8-K on January 21, 2025, reporting an event on January 16, 2025. The filing primarily concerns financial statements and exhibits, with no specific material events detailed in the provided text.
Why It Matters
This filing indicates Keros Therapeutics is providing updated financial statements and exhibits to the SEC, which is standard procedure but may contain details relevant to investors.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for financial statements and exhibits, not indicating any immediate material changes or risks.
Key Players & Entities
- Keros Therapeutics, Inc. (company) — Registrant
- January 16, 2025 (date) — Earliest event reported
- January 21, 2025 (date) — Date of report
- 1050 Waltham Street, Suite 302 (address) — Principal executive offices
- Lexington, Massachusetts (location) — Principal executive offices
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report other events and to provide financial statements and exhibits as of January 16, 2025.
When was this 8-K filed with the SEC?
This 8-K was filed on January 21, 2025.
What is the exact name of the registrant?
The exact name of the registrant is Keros Therapeutics, Inc.
What is the state of incorporation for Keros Therapeutics, Inc.?
Keros Therapeutics, Inc. is incorporated in Delaware.
What is the address of Keros Therapeutics, Inc.'s principal executive offices?
The address of Keros Therapeutics, Inc.'s principal executive offices is 1050 Waltham Street, Suite 302, Lexington, Massachusetts 02421.
Filing Stats: 542 words · 2 min read · ~2 pages · Grade level 10.4 · Accepted 2025-01-21 08:01:40
Key Financial Figures
- $0.0001 — ge on which registered Common Stock, $0.0001 par value per share KROS The Nasdaq Sto
- $200.0 m — ke an upfront payment to the Company of $200.0 million, as previously disclosed in the C
Filing Documents
- kros-20250116.htm (8-K) — 37KB
- exhibit99112125pr.htm (EX-99.1) — 7KB
- 0001664710-25-000008.txt ( ) — 170KB
- kros-20250116.xsd (EX-101.SCH) — 2KB
- kros-20250116_lab.xml (EX-101.LAB) — 22KB
- kros-20250116_pre.xml (EX-101.PRE) — 13KB
- kros-20250116_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events. On December 3, 2024, Keros Therapeutics, Inc. (the "Company") entered into an Exclusive License Agreement (the "Agreement") with Takeda Pharmaceuticals U.S.A., Inc. ("Takeda"), which provides that the Agreement becomes effective upon the expiration or termination of applicable waiting period under the Hart-Scott Rodino Antitrust Improvements Act of 1976, as amended (the "HSR Act"). The expiration of the applicable waiting period under the HSR Act was on January 16, 2025, and the Agreement became effective on January 16, 2025. In connection with the effectiveness of the Agreement, Takeda will make an upfront payment to the Company of $200.0 million, as previously disclosed in the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on December 3, 2024. A copy of the press release announcing the effectiveness of the Agreement is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release dated January 21 , 2025. 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. KEROS THERAPEUTICS, INC. By: /s/ Jasbir Seehra Jasbir Seehra, Ph.D. Chief Executive Officer Dated: January 21, 2025